Compare TransMedics Group Inc (TMDX) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: TransMedics Group Inc is far larger — about 4.9× Direxion Daily FTSE China Bull 3x Shares's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 1,009,521). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| TMDX | YINN | |
|---|---|---|
Market Cap | $2.74B | $560.32M |
Volume | 949,331 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $150.42 | $52.69 |
52-Week Low | $61.99 | $21.45 |
Typical Hold Time | 24 Days | 25 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
YINN is trading at $25.27, up 7.26% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed fundamental ratios such as P/E and P/S, and recent news highlights China's economic policies and energy sector dynamics, which may influence its performance. Support is clustered around $23, with resistance at $24.
The outlook remains cautious due to bearish technicals and limited fundamental visibility. Risks include reliance on Chinese economic conditions and potential regulatory changes. Investment opportunities hinge on improved earnings transparency and positive shifts in market sentiment, but current data suggests a neutral to bearish stance for near-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
